Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 13/20 | 0.38 |
| ▸ | TCF7L2 | Q9NQB0 | 13/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101129 | 1.00 | FLT3 (0.40) | FLT3CTNNB1TCF7L2BTKDYRK1A | |
| SCHEMBL5089548 | 0.88 | BTK (0.36) | FLT3CTNNB1TCF7L2BTKDYRK1A | |
| SCHEMBL4874129 | 0.87 | MKNK1 (0.38) | BTKDYRK1ACLK1GSK3BGSK3A | |
| SCHEMBL4874122 | 0.87 | MKNK1 (0.38) | BTKDYRK1ACLK1GSK3BGSK3A | |
| SCHEMBL5094445 | 0.86 | MKNK1 (0.42) | FLT3DYRK1AGSK3BGSK3AMKNK1 | |
| SCHEMBL5094441 | 0.86 | MKNK1 (0.42) | FLT3DYRK1AGSK3BGSK3AMKNK1 | |
| Hydrochloric Acid SCHEMBL5089751 | 0.85 | CDC7 (0.40) | FLT3BTKDYRK1AGSK3BGSK3A | |
| Hydrochloric Acid SCHEMBL5089735 | 0.85 | CDC7 (0.40) | FLT3BTKDYRK1AGSK3BGSK3A | |
| SCHEMBL5095265 | 0.84 | CLK1 (0.50) | FLT3DYRK1ACLK1 | |
| SCHEMBL5095269 | 0.84 | CLK1 (0.50) | FLT3DYRK1ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | FLT3 590/4885CTNNB1 1012/4885TCF7L2 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.